AstraZeneca, Myriad Genetics team to trial ovarian cancer drugs

CG image of AstraZeneca's HQ
AstraZeneca's new headquarters (Courtesy of AstraZeneca)

AstraZeneca and Myriad Genetics are partnering to identify women with advanced ovarian cancer who might benefit from treatments using Lynparza and Avastin as part of a phase 3 trial.

Under the partnership, Myriad’s myChoice HRD Plus test will be used to identify patients already enrolled in the trial who have homologous recombination deficiencies (HRD). Financial terms of the agreement weren’t disclosed.

“MyChoice HRD Plus is the most comprehensive test for identifying defects in DNA repair pathways,” Jerry Lanchbury, Ph.D., chief scientific officer for Myriad, said in a statement. “We are optimistic that myChoice HRD Plus will identify more women with ovarian cancer who could benefit from therapy with Lynparza than previous tests that only identify germline BRCA1/2 mutations.”


Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

The two companies have been working together since 2007 when they teamed to develop a companion diagnostic test to identify candidates for treatment with olaparib. Four years ago, Myriad got the FDA nod for its BRACAnalysis CDx to identify patients with advanced ovarian cancer who are eligible for fourth-line treatment with olaparib. BRACAnalysis CDx was the first-ever laboratory-developed test approved by the regulatory agency.

In November, Myriad announced it partnered with CareFirst BlueCross BlueShield to evaluate a multibiomarker rheumatoid arthritis blood test. The 18-month study will assess whether Vectra DA delivers better outcomes and lower costs than conventional approaches.

Suggested Articles

The FDA broadened its approval of Medtronic’s transcatheter aortic valve replacement to include patients at a low risk of surgical complications.

The FDA approved the first spinal tether to correct the most common form of scoliosis—a ropelike implant that pulls the vertebrae into shape.

Agilent launched a new analyzer for research that observes cell behavior in real time while also collecting biosensor information.